EUVIMEDEUVIMED entdecken
Kommentar

Targeting DLK1 in neuroblastoma

John Anderson

Cancer Cell · 2024

DOI: 10.1016/j.ccell.2024.10.006 ↗

Kurz gefasst

Kommentar in der Zeitschrift Cancer Cell, 2024. Verfasst von John Anderson. Beteiligte Einrichtung: UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK. Electronic address: j.anderson@ucl.ac.uk. Hauptthemen laut MEDLINE: Neuroblastoma, Calcium-Binding Proteins. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An ideal cell surface target has ubiquitously high cancer expression, absence from healthy tissues, and an essential role cancer initiation and/or maintenance. In this issue of Cancer Cell, Hamilton et al. combine proteomics, transcriptomics, epigenomics, and dependency databases to identify DLK1, a novel immunotherapeutic target for neuroblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaCalcium-Binding ProteinsHumansIntercellular Signaling Peptides and ProteinsAnimalsMembrane ProteinsGene Expression Regulation, NeoplasticMolecular Targeted Therapy

Substanzen

DLK1 protein, humanCalcium-Binding ProteinsIntercellular Signaling Peptides and ProteinsMembrane Proteins

Autor:innen und Institutionen

  • UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK. Electronic address: j.anderson@ucl.ac.uk.

Zitieren

APA

Anderson, J. (2024). Targeting DLK1 in neuroblastoma. Cancer Cell. https://doi.org/10.1016/j.ccell.2024.10.006

Vancouver

Anderson J. Targeting DLK1 in neuroblastoma. Cancer Cell. 2024. doi:10.1016/j.ccell.2024.10.006

BibTeX
@article{Anderson2024,
  author = {Anderson, John},
  title = {Targeting DLK1 in neuroblastoma},
  journal = {Cancer Cell},
  year = {2024},
  doi = {10.1016/j.ccell.2024.10.006}
}
Kostenlos starten →